Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 4Ovarian Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1Metastatic Bladder Urothelial Carcinoma 1Leiomyosarcoma 1Clinical Stage III Gastric Cancer AJCC v8 1Carcinoma, Neuroendocrine 1Brain Neoplasms 1

Interventions

Everolimus 5Topotecan 2Etoposide 2Cisplatin 2Bevacizumab 2veliparib 1pralsetinib 1pertuzumab 1pembrolizumab 1pasireotide 1lenvatinib 1carfilzomib 1cabozantinib 1berzosertib 1Temozolomide 1Sunitinib 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Podophyllotoxin 1Platinum 1Octreotide 1Nivolumab 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Carboplatin 1Capecitabine 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Neuroendocrine × berzosertib × Clear all
NCT02487095 2025-04-13

Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
62 enrolled 29 charts
EndocrineGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡